Related Experiment Video
Updated: Jun 21, 2025
Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
Selective STAT3 inhibitor STX-0119 alleviates osteoarthritis progression by modulating the STAT3/PPARγ signaling
Xuanyuan Lu1, Yangjun Xu2, Xinhuo Li2
1Department of Orthopedic, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China; Department of Orthopedic, Shaoxing People's Hospital, Shaoxing 312000, Zhejiang, China.
Abstract:
Osteoarthritis (OA), characterized by chronic pain, significantly affects the quality of life of affected individuals. Key factors in OA pathogenesis include cartilage degradation and inflammation. Signal transducer and activator of transcription 3 (STAT3), a member of the STAT protein family, plays a pivotal role in mediating inflammation. STX-0119 has been verified as a small molecular compound that can specifically inhibit STAT3. However, the efficacy of STX-0119 in the treatment of OA remains to be evaluated. Therefore, the aim of this study was to explore the therapeutic effects and molecular mechanisms of STX-0119 in the treatment of OA. We found that the expression of phosphorylated STAT3 is upregulated in human OA cartilage as well as in the cartilage of a mouse model of OA. In vivo, joint injection of STX-0119 into OA mice alleviated cartilage degeneration without affecting the subchondral bone. Additionally, STX-0119 could inhibit the phosphorylation of STAT3 in the cartilage. In vitro, STX-0119 suppressed inflammatory responses in chondrocytes and promoted anabolic metabolism in an interleukin-1β-induced chondrocyte inflammation model. Additionally, the results of transcriptome sequencing and lentiviral infection assays demonstrated that in chondrocytes, STX-0119 induces the upregulation of peroxisome proliferators-activated receptor gamma (PPARγ) expression by inhibiting STAT3 phosphorylation. Finally, in ex vivo cultures of human cartilage samples, STX-0119 was reaffirmed to inhibit cartilage degeneration via the STAT3/PPARγ signaling pathway. Together, our findings support the potential of STX-0119 for development as a therapeutic agent targeting STAT3 for the treatment of OA.
Insights
STX-0119, a novel compound, effectively treats osteoarthritis (OA) by inhibiting STAT3 phosphorylation, reducing cartilage degradation, and modulating inflammation via the STAT3/PPARγ pathway.
Area of Science:
- Biomedical research
- Molecular biology
- Pharmacology
Background:
- Osteoarthritis (OA) is a debilitating condition marked by chronic pain and cartilage degradation.
- Inflammation, mediated by Signal Transducer and Activator of Transcription 3 (STAT3), is a key factor in OA pathogenesis.
- STX-0119 is a small molecule inhibitor of STAT3, but its efficacy in OA treatment requires investigation.
Purpose of the Study:
- To investigate the therapeutic potential and molecular mechanisms of STX-0119 in treating osteoarthritis.
- To evaluate the effect of STX-0119 on STAT3 signaling and cartilage health in OA models.
Main Methods:
- In vivo studies using a mouse model of OA and ex vivo cultures of human cartilage.
- In vitro experiments on chondrocytes, including interleukin-1β-induced inflammation models.
- Transcriptome sequencing and lentiviral infection assays to elucidate molecular pathways.
Main Results:
- Phosphorylated STAT3 expression is elevated in human and mouse OA cartilage.
- STX-0119 administration in OA mice reduced cartilage degeneration and inhibited STAT3 phosphorylation.
- In vitro, STX-0119 suppressed chondrocyte inflammation and promoted anabolic metabolism.
- STX-0119 upregulates PPARγ expression by inhibiting STAT3 phosphorylation in chondrocytes.
Conclusions:
- STX-0119 demonstrates significant therapeutic effects in preclinical OA models.
- The mechanism involves inhibition of STAT3 phosphorylation, leading to PPARγ upregulation and reduced cartilage degeneration.
- STX-0119 holds promise as a novel therapeutic agent for osteoarthritis targeting the STAT3 pathway.
